These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
188 related articles for article (PubMed ID: 6930877)
1. Current concepts in the overall management of thalassemia. Propper RD Ann N Y Acad Sci; 1980; 344():375-83. PubMed ID: 6930877 [No Abstract] [Full Text] [Related]
2. Iron overload: pathogenesis and treatment with chelating agents. Huebers H Blut; 1983 Aug; 47(2):61-7. PubMed ID: 6871476 [No Abstract] [Full Text] [Related]
3. Improved oxygen delivery to tissues and iron chelator transport through the use of lysed and resealed red blood cells: a new perspective on Cooley's anemia therapy. Ropars C; Teisseire B; Avenard G; Chassaigne M; Hurel C; Girot R; Nicolau C Ann N Y Acad Sci; 1985; 445():304-15. PubMed ID: 3860134 [No Abstract] [Full Text] [Related]
4. Iron metabolism and iron chelation in the thalassaemia disorders. Pippard MJ Haematologica; 1990; 75 Suppl 5():66-71. PubMed ID: 2086383 [No Abstract] [Full Text] [Related]
5. Management of thalassemia in Los Angeles. Hyman CB; Ortega JA; Costin G; Landing B; Lazerson J; Leimbrock S; Lurie P Birth Defects Orig Artic Ser; 1976; 12(8):43-52. PubMed ID: 1009234 [No Abstract] [Full Text] [Related]
7. Treatment of iron overload in Cooley's anemia. Cohen A; Mizanin J; Schwartz E Ann N Y Acad Sci; 1985; 445():274-81. PubMed ID: 3860130 [No Abstract] [Full Text] [Related]
10. Clinical management of thalassemia. Decreasing iron stores during intensive chelation therapy. Cohen A; Schwartz E Ann N Y Acad Sci; 1980; 344():405-8. PubMed ID: 6930880 [No Abstract] [Full Text] [Related]
12. Current strategies in the management of Cooley's anemia. Piomelli S; Hart D; Graziano J; Grant G; Karpatkin M; McCarthy K Ann N Y Acad Sci; 1985; 445():256-67. PubMed ID: 3860128 [No Abstract] [Full Text] [Related]
13. Chelation therapy, transfusion requirement, and iron balance in young thalassemic patients. Piomelli S; Graziano J; Karpatkin M; Dudell GG; Hart D; Hilgartner M; Khanna K; Valdes-Cruz LM; Vora S Ann N Y Acad Sci; 1980; 344():409-17. PubMed ID: 6930881 [No Abstract] [Full Text] [Related]
14. [Current status of treatments with desferrioxamine B in post-transfusion hypersiderosis in children]. Orsini A; Raybaud C; Bernard PJ; Aquaron R; Passeron P Mars Med; 1967; 104(4):331-7. PubMed ID: 5621537 [No Abstract] [Full Text] [Related]
15. Residual erythropoiesis protects against myocardial hemosiderosis in transfusion-dependent thalassemia by lowering labile plasma iron via transient generation of apotransferrin. Garbowski MW; Evans P; Vlachodimitropoulou E; Hider R; Porter JB Haematologica; 2017 Oct; 102(10):1640-1649. PubMed ID: 28642302 [TBL] [Abstract][Full Text] [Related]
16. Iron chelating therapy in thalassemia: current problems. Russo G Haematologica; 1990; 75 Suppl 5():84-8. PubMed ID: 2086385 [No Abstract] [Full Text] [Related]
17. [Evaluation of iron balance in homozygous beta-thalassemia subjects treated with desferrioxamine administered subcutaneously]. Ferrara M; Galdo Capotorti M; Ponte G; Esposito L Pediatria (Napoli); 1983; 91(4):371-7. PubMed ID: 6545400 [No Abstract] [Full Text] [Related]
18. Desferrioxamine-chelatable iron (DCI), a component of serum non-transferrin-bound iron (NTBI) used for assessing iron chelation therapy. Breuer W; Ermers MJ; Pootrakul P; Abramov A; Hershko C; Cabantchik ZI Transfus Sci; 2000 Dec; 23(3):241-2. PubMed ID: 11099901 [No Abstract] [Full Text] [Related]
19. [Hypertransfusion, chelating and immunocorrective therapy in beta-thalassemia major]. Zeĭnalova AA; Ragimov AA; Dashkova NG; Mamedova FR; Kurbanova SA Pediatriia; 1987; (2):55-60. PubMed ID: 3575062 [No Abstract] [Full Text] [Related]
20. Editorial: Thalassemia major: a problem of iron overload. Stockman JA; Oski FA Ann Intern Med; 1974 Aug; 81(2):262-3. PubMed ID: 4846109 [No Abstract] [Full Text] [Related] [Next] [New Search]